COVID-19
Infectious disease · 2022–2026
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| mRNA-1273 Prevention of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 in four populations of adults: (1) aged 75 years or more (2 doses per year); (2) aged… | Mar 2026 | Deferred | input received Pharmaceutical Society of Australia · Lung Foundation Australia |
| raxtozinameran Prevention of COVID-19 disease caused by SARS-CoV-2 virus in adults aged ≥18 years at increased risk of severe COVID-19 disease. | Dec 2025 | Deferred | 1 individuals Lung Foundation Australia · National Aboriginal Community Controlled Health Organisation |
| molnupiravir Treatment of patients with mild to moderate COVID-19 who are at high risk of severe disease requiring hospitalisation. | Nov 2023 | Deferred | 1 individuals Kirby Institute · Lung Foundation Australia · Immunisation Coalition |
| nirmatrelvir and ritonavir Treatment of patients with mild to moderate Coronavirus disease (COVID-19) who are at high risk of severe disease requiring hospitalisation. | Nov 2023 | Recommended with restriction | 3 individuals Lung Foundation Australia · Rare Cancers Australia |
| tixagevimab and cilgavimab Pre-exposure prophylaxis (PrEP) of COVID-19 in adults and adolescents aged 12 years and older who are severely immunocompromised or in whom vaccination with… | Sep 2022 | Not recommended | no section in document |
Who spoke
Lung Foundation Australia · Kirby Institute · Immunisation Coalition · Rare Cancers Australia · National Aboriginal Community Controlled Health Organisation · Pharmaceutical Society of Australia
What the PBS pays
$216M in government benefit over 2024–25, across 199,042 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| molnupiravir | $215.4M |
| nirmatrelvir and ritonavir | $0.3M |
Appraised elsewhere
NICE, in England and Wales, has appraised 4 technologies for this condition, recommending 3 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| molnupiravirMolnupiravir for treating COVID-19 | TA1056 | recommended restricted | 2025-04 |
| remdesivir and tixagevimab plus cilgavimabRemdesivir and tixagevimab plus cilgavimab for treating COVID-19 | TA971 | recommended restricted | 2024-05 |
| tixagevimab plus cilgavimabTixagevimab plus cilgavimab for preventing COVID-19 | TA900 | not recommended | 2023-06 |
| nirmatrelvir plus ritonavir and tocilizumabNirmatrelvir plus ritonavir and tocilizumab for treating COVID-19 | TA878 | recommended restricted | 2023-03 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| sars covCOMIRNATY LP.8.1 (SARS-CoV-2 spike protein (mRNA) LP.8.1) COVID-19 VAC | 2022 | 9 |
| bretovameranCOMIRNATY JN.1 (bretovameran) COVID-19 VACCINE 10 micrograms/0.2 mL co | 2024 | 9 |
| famtozinameran + tozinameranCOMIRNATY ORIGINAL/OMICRON BA.4-5 (tozinameran/famtozinameran) COVID-1 | 2023 | 6 |
| davesomeran + elasomeranSPIKEVAX BIVALENT ORIGINAL/OMICRON BA.4-5 (elasomeran/davesomeran) COV | 2023 | 3 |
| elasomeranSPIKEVAX (elasomeran) COVID-19 VACCINE 0.1 mg/mL suspension for injec | 2021 | 3 |
| andusomeranSPIKEVAX XBB.1.5 (andusomeran) COVID-19 VACCINE 0.1 mg/mL suspension f | 2023 | 2 |
| sipavibartKAVIGALE, sipavibart, 300 mg in 2 mL (150 mg/mL), Solution for injecti | 2025 | 1 |
| remdesivirVEKLURY remdesivir 100 mg powder for injection vial | 2020 | 1 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 4 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.